Sartorius AG

euro adhoc: Sartorius AG
quarterly or semiannual financial statement
Group sales revenue climbed 15.1%; currency-adjusted, up 12.5%
EBITDA improved 48.9% to EUR16.4 million
EBIT up 80.2% to EUR11.7 million
Earnings per share: EUR0.37 (Q1 of 200

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

20.04.2006

During the first three months of 2006, sales revenue of the Sartorius Group rose 15.1% (currency-adjusted: +12.5%) to EUR128.6 million (Q1 of 2005: EUR111.8 mn). Sales revenue for the Biotechnology Division climbed 15.8% (currency-adjusted: +13.2%) to EUR68.2 million (EUR58.9 mn). For the Mechatronics Division, sales revenue grew 14.3% (currency-adjusted: +11.7%) to EUR60.4 million (EUR52.9 mn). Up 15.8% (currency-adjusted: +12.8%) to EUR132.7 million (EUR114.6 mn), Group order intake also showed positive development (currency-adjusted for Biotechnology Division: +20.8%; currency-adjusted for Mechatronics Division: +5.2%).

Earnings before interest, taxes, depreciation and amortization (EBITDA) increased from EUR11.0 million to EUR16.4 million (+48.9%). EBIT, earnings before interest and taxes, soared 80.2% to EUR11.7 million (EUR6.5 mn). The EBIT margin improved from 5.8% to 9.1%. EBIT for the Biotechnology Division rose from EUR4.3 million to EUR7.3 million; that of the Mechatronics Division, from EUR2.2 million to EUR4.4 million. At EUR6.3 million, net profit for the period also substantially surpassed the year-earlier quarterly figure (EUR2.2 million); earnings per share were EUR0.37, up from EUR0.13 a year ago.

At EUR3.1 million (EUR8.1 mn), net cash flow was positive and primarily used to reduce net debt by EUR1.8 million to EUR58.9 million.

In comparison to the relatively moderate year-earlier quarter, sales revenue growth was above-average. For the full year, we further expect to increase sales revenue by more than 5% based on constant currencies and to post earnings before interest and taxes of approximately 10% of sales revenue.

@@start.t2@@end of announcement                                                 euro adhoc 20.04.2006 07:24:35
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Andreas Wiederhold
Phone +49.551.308.1668
andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / official dealing/prime standard
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bayerische Börse / free trade
              Niedersächsische Börse zu Hannover / official dealing



Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: